NAD+

NAD+ (Nicotinamide adenine dinucleotide) is a coenzyme (not a peptide). The HEIVE catalog describes it as: A coenzyme every cell needs to make energy. Levels fall with age, and the entire longevity case rests on putting them back. It is also known as Nicotinamide adenine dinucleotide.

HEIVE groups NAD+ under fatigue, mitochondrial function, energy crashes, oxidative stress and cellular maintenance. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for NAD+ under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products.

• FDA product data (October 6, 2026)

The HEIVE editorial risk summary for NAD+ lists: Pushed too fast it causes chest pressure, nausea and cramping. The drip rate is the whole game. Longer-term concerns: Unknown. Whether raising NAD+ feeds an existing tumour is an open and serious question. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

NAD+ has no single onset time established by this catalog. The editorial timeline starts with “First sessions”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for NAD+: 250–500 mg subcutaneously per session, two to three sessions a week. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies NAD+ as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists sublingual, topical or a nasal form for NAD+. A listed form is not evidence of an approved or effective treatment. Nasal forms are listed in the source catalog; this does not establish approval, efficacy or equivalent absorption. HEIVE injection calculations do not apply to nasal forms.

Preparation of NAD+ depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for NAD+ depends on the specific formulation (injectable, sublingual, topical and nasal in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for NAD+: None. Loading course, then monthly maintenance, is the common pattern. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

NAD+ and SS-31 share the catalog categories mitochondrial function, oxidative stress and fatigue. NAD+: A coenzyme every cell needs to make energy. Levels fall with age, and the entire longevity case rests on putting them back. SS-31: Binds cardiolipin in the inner mitochondrial membrane; in late-stage trials for primary mitochondrial myopathy. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View SS-31

The HEIVE editorial summary highlights: Infusion work aimed at energy kept reporting alcohol and stimulant cravings dropping. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.